Acute manifestations of ischemic heart disease are among the most serious and fatal consequences of atherosclerotic processes. In this study, we hypothesized that a soluble proprotein convertase subtilisin/kexin type 9 (PCSK9), soluble bone morphogenetic protein 4 (BMP-4), soluble E-selectin (sE-selectin), soluble endoglin (sENG) and soluble endocan (Endocan) would differ from healthy controls in myocardial infarction (MI) patients admitted to the hospital without any previous history of cardiovascular disease and with no cardioprotective drugs taken before admission. The study was conducted using a cross-sectional design. We analyzed data from 79 patients (mean age 54.1 ± 8.9, 18% of women) admitted for the first manifestation of MI and with no history of cardioprotective treatment use before the event. As a control group, we analyzed 17 age-matched healthy volunteers (mean age 51.5 ± 8.6, 47% of women). In addition to routinely obtaining clinical and laboratory data, we analyzed plasma concentrations of the aforementioned biomarkers using ELISA and Luminex analyses. Patients with MI did not differ from healthy controls in total cholesterol, LDL, non-HDL, and triglyceride levels. PCSK9, BMP-4, and sE-selectin levels did not differ significantly between the MI and the control group. Patients with MI had significantly higher sENG and Endocan levels than the control group. In addition, levels of sENG were significantly higher in patients with higher body mass index (BMI) and in smokers. We demonstrated that sENG could serve as a biomarker reflecting endothelial dysfunction in MI patients without prior treatment for cardiovascular risk factors.

Cardiology Department Cardiac Centre Institute for Clinical and Experimental Medicine Prague Czech Republic

Department of Biological and Medical Sciences Faculty of Pharmacy in Hradec Králové Charles University Prague Czech Republic

Department of Immunology and Allergology University Hospital Hradec Králové and Charles University Faculty of Medicine in Hradec Králové Czech Republic

Department of PISA Cardiac Centre Institute for Clinical and Experimental Medicine Prague Czech Republic

Zobrazit více v PubMed

Mitsis A, Myrianthefs M, Sokratous S, Karmioti G, Kyriakou M, Drakomathioulakis M. et al. Emerging Therapeutic Targets for Acute Coronary Syndromes: Novel Advancements and Future Directions. Biomedicines. 2024;12:1670. PubMed PMC

Katsioupa M, Kourampi I, Oikonomou E, Tsigkou V, Theofilis P, Charalambous G. et al. Novel Biomarkers and Their Role in the Diagnosis and Prognosis of Acute Coronary Syndrome. Life (Basel) 2023;13:13. 1992. PubMed PMC

Medina-Leyte DJ, Zepeda-Garcia O, Dominguez-Perez M, Gonzalez-Garrido A, Villarreal-Molina T, Jacobo-Albavera L. Endothelial Dysfunction, Inflammation and Coronary Artery Disease: Potential Biomarkers and Promising Therapeutical Approaches. Int J Mol Sci. 2021;22:3850. PubMed PMC

Leite AR, Borges-Canha M, Cardoso R, Neves JS, Castro-Ferreira R, Leite-Moreira A. Novel Biomarkers for Evaluation of Endothelial Dysfunction. Angiology. 2020;71:397–410. PubMed

Paryani M, Gupta N, Jain SK, Butani S. Lowering LDL cholesterol by PCSK9 inhibition: a new era of gene silencing, RNA, and alternative therapies. Naunyn Schmiedebergs Arch Pharmacol. 2025;398:6597–6615. PubMed

Ragusa R, Basta G, Neglia D, De Caterina R, Del Turco S, Caselli C. PCSK9 and atherosclerosis: Looking beyond LDL regulation. Eur J Clin Invest. 2021;51:e13459. PubMed

Helbing T, Arnold L, Wiltgen G, Hirschbihl E, Gabelmann V, Hornstein A. et al. Endothelial BMP4 Regulates Leukocyte Diapedesis and Promotes Inflammation. Inflammation. 2017;40:1862–74. PubMed

Gallardo-Vara E, Gamella-Pozuelo L, Perez-Roque L, Bartha JL, Garcia-Palmero I, Casal JI. et al. Potential Role of Circulating Endoglin in Hypertension via the Upregulated Expression of BMP4. Cells. 2020;9:988. PubMed PMC

Schoonderwoerd MJA, Goumans MTH, Hawinkels L. Endoglin: Beyond the Endothelium. Biomolecules. 2020;10:289. PubMed PMC

Oujo B, Perez-Barriocanal F, Bernabeu C, Lopez-Novoa JM. Membrane and soluble forms of endoglin in preeclampsia. Curr Mol Med. 2013;13:1345–57. PubMed

Aristorena M, Gallardo-Vara E, Vicen M, de Las Casas-Engel M, Ojeda-Fernandez L, Nieto C. et al. MMP-12, Secreted by Pro-Inflammatory Macrophages, Targets Endoglin in Human Macrophages and Endothelial Cells. Int J Mol Sci. 2019;20:3107. PubMed PMC

Hawinkels LJ, Kuiper P, Wiercinska E, Verspaget HW, Liu Z, Pardali E. et al. Matrix metalloproteinase-14 (MT1-MMP)-mediated endoglin shedding inhibits tumor angiogenesis. Cancer Res. 2010;70:4141–50. PubMed

Valbuena-Diez AC, Blanco FJ, Oujo B, Langa C, Gonzalez-Nunez M, Llano E. et al. Oxysterol-induced soluble endoglin release and its involvement in hypertension. Circulation. 2012;126:2612–24. PubMed

El Hamaoui D, Marchelli A, Gandrille S, Reboul E, Stepanian A, Palmier B. et al. Thrombin cleaves membrane-bound endoglin potentially contributing to the heterogeneity of circulating endoglin in preeclampsia. Commun Biol. 2025;8:316. PubMed PMC

Leanos-Miranda A, Navarro-Romero CS, Sillas-Pardo LJ, Ramirez-Valenzuela KL, Isordia-Salas I, Jimenez-Trejo LM. Soluble Endoglin as a Marker for Preeclampsia, Its Severity, and the Occurrence of Adverse Outcomes. Hypertension. 2019;74:991–7. PubMed

Blann AD, Wang JM, Wilson PB, Kumar S. Serum levels of the TGF-beta receptor are increased in atherosclerosis. Atherosclerosis. 1996;120:221–6. PubMed

Visek J, Blaha M, Blaha V, Lasticova M, Lanska M, Andrys C. et al. Monitoring of up to 15 years effects of lipoprotein apheresis on lipids, biomarkers of inflammation, and soluble endoglin in familial hypercholesterolemia patients. Orphanet J Rare Dis. 2021;16:110. PubMed PMC

Rathouska J, Vecerova L, Strasky Z, Slanarova M, Brcakova E, Mullerova Z. et al. Endoglin as a possible marker of atorvastatin treatment benefit in atherosclerosis. Pharmacol Res. 2011;64:53–9. PubMed

Malhotra R, Paskin-Flerlage S, Zamanian RT, Zimmerman P, Schmidt JW, Deng DY. et al. Circulating angiogenic modulatory factors predict survival and functional class in pulmonary arterial hypertension. Pulm Circ. 2013;3:369–80. PubMed PMC

Tomaskova V, Mytnikova A, Hortova Kohoutkova M, Mrkva O, Skotakova M, Sitina M. et al. Prognostic value of soluble endoglin in patients with septic shock and severe COVID-19. Front Med (Lausanne) 2022;9:972040. PubMed PMC

Eissazadeh S, Mohammadi S, Faradonbeh FA, Rathouska JU, Nemeckova I, Tripska K. et al. Endoglin and soluble endoglin in liver sinusoidal endothelial dysfunction in vivo. Biochim Biophys Acta Mol Basis Dis. 2024;1870:166990. PubMed

Vicen M, Vitverova B, Havelek R, Blazickova K, Machacek M, Rathouska J. et al. Regulation and role of endoglin in cholesterol-induced endothelial and vascular dysfunction in vivo and in vitro. FASEB J. 2019;33:6099–114. PubMed

Rathouska J, Jezkova K, Nemeckova I, Nachtigal P. Soluble endoglin, hypercholesterolemia and endothelial dysfunction. Atherosclerosis. 2015;243:383–8. PubMed

Vitverova B, Blazickova K, Najmanova I, Vicen M, Hyspler R, Dolezelova E. et al. Soluble endoglin and hypercholesterolemia aggravate endothelial and vessel wall dysfunction in mouse aorta. Atherosclerosis. 2018;271:15–25. PubMed

Varejckova M, Gallardo-Vara E, Vicen M, Vitverova B, Fikrova P, Dolezelova E. et al. Soluble endoglin modulates the pro-inflammatory mediators NF-kappaB and IL-6 in cultured human endothelial cells. Life Sci. 2017;175:52–60. PubMed

Cruz-Gonzalez I, Pabon P, Rodriguez-Barbero A, Martin-Moreiras J, Pericacho M, Sanchez PL. et al. Identification of serum endoglin as a novel prognostic marker after acute myocardial infarction. J Cell Mol Med. 2008;12:955–61. PubMed PMC

Cui S, Lu SZ, Chen YD, He GX, Meng LJ, Liu JP. et al. Relationship among soluble CD105, hypersensitive C-reactive protein and coronary plaque morphology: an intravascular ultrasound study. Chin Med J (Engl) 2008;121:128–32. PubMed

Chen J, Jiang L, Yu XH, Hu M, Zhang YK, Liu X. et al. Endocan: A Key Player of Cardiovascular Disease. Front Cardiovasc Med. 2021;8:798699. PubMed PMC

Qiu CR, Fu Q, Sui J, Zhang Q, Wei P, Wu Y. et al. Endocan: Endothelial Dysfunction, Inflammation, or Both? Angiology. 2017;68:80. PubMed

Gok M, Kundi H, Kiziltunc E, Topcuoglu C, Ornek E. Endocan Levels and Coronary Collateral Circulation in Stable Angina Pectoris: A Pilot Study. Angiology. 2018;69:43–8. PubMed

Behnoush AH, Khalaji A, Bahiraie P, Alehossein P, Shobeiri P, Peisepar M. et al. Endocan as a marker of endothelial dysfunction in hypertension: a systematic review and meta-analysis. Hypertens Res. 2023;46:2388–99. PubMed

Kose M, Emet S, Akpinar TS, Kocaaga M, Cakmak R, Akarsu M. et al. Serum Endocan Level and the Severity of Coronary Artery Disease: A Pilot Study. Angiology. 2015;66:727–31. PubMed

Bessa J, Albino-Teixeira A, Reina-Couto M, Sousa T. Endocan: A novel biomarker for risk stratification, prognosis and therapeutic monitoring in human cardiovascular and renal diseases. Clin Chim Acta. 2020;509:310–35. PubMed

Cristina Igreja Sa I, Tripska K, Alaei Faradonbeh F, Hroch M, Lastuvkova H, Schreiberova J. et al. Labetalol and soluble endoglin aggravate bile acid retention in mice with ethinylestradiol-induced cholestasis. Front Pharmacol. 2023;14:1116422. PubMed PMC

Wohlfahrt P, Jenca D, Melenovsky V, Sramko M, Kotrc M, Zelizko M. et al. Trajectories and determinants of left ventricular ejection fraction after the first myocardial infarction in the current era of primary coronary interventions. Front Cardiovasc Med. 2022;9:1051995. PubMed PMC

Wohlfahrt P, Jenca D, Stehlik J, Melenovsky V, Mrazkova J, Stanek V. et al. Heart failure-related quality-of-life impairment after myocardial infarction. Clin Res Cardiol. 2023;112:39–48. PubMed

Varjabedian L, Bourji M, Pourafkari L, Nader ND. Cardioprotection by Metformin: Beneficial Effects Beyond Glucose Reduction. Am J Cardiovasc Drugs. 2018;18:181–93. PubMed

Pedersen TR. Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering. Am J Cardiovasc Drugs. 2010;10(Suppl 1):10–7. PubMed

Saita E, Miura K, Suzuki-Sugihara N, Miyata K, Ikemura N, Ohmori R. et al. Plasma Soluble Endoglin Levels Are Inversely Associated With the Severity of Coronary Atherosclerosis-Brief Report. Arterioscler Thromb Vasc Biol. 2017;37:49–52. PubMed

Rathouska J, Fikrova P, Mrkvicova A, Blazickova K, Varejckova M, Dolezelova E. et al. High soluble endoglin levels do not induce changes in structural parameters of mouse heart. Heart Vessels. 2017;32:1013–24. PubMed

Heffernan KS, Kuvin JT, Patel AR, Karas RH, Kapur NK. Endothelial function and soluble endoglin in smokers with heart failure. Clin Cardiol. 2011;34:729–33. PubMed PMC

Kapur NK, Heffernan KS, Yunis AA, Parpos P, Kiernan MS, Sahasrabudhe NA. et al. Usefulness of soluble endoglin as a noninvasive measure of left ventricular filling pressure in heart failure. Am J Cardiol. 2010;106:1770–6. PubMed PMC

Vicen M, Igreja Sa IC, Tripska K, Vitverova B, Najmanova I, Eissazadeh S. et al. Membrane and soluble endoglin role in cardiovascular and metabolic disorders related to metabolic syndrome. Cell Mol Life Sci. 2021;78:2405–2418. PubMed PMC

Gallardo-Vara E, Tual-Chalot S, Botella LM, Arthur HM, Bernabeu C. Soluble endoglin regulates expression of angiogenesis-related proteins and induction of arteriovenous malformations in a mouse model of hereditary hemorrhagic telangiectasia. Dis Model Mech. 2018;11:dmm034397. PubMed PMC

Chen Y, Hao Q, Kim H, Su H, Letarte M, Karumanchi SA. et al. Soluble endoglin modulates aberrant cerebral vascular remodeling. Ann Neurol. 2009;66:19–27. PubMed PMC

Yu J, Li Y, Hu J, Wang Y. Interleukin-33 induces angiogenesis after myocardial infarction via AKT/eNOS signaling pathway. Int Immunopharmacol. 2024;143:113433. PubMed

Zhao T, Kecheng Y, Zhao X, Hu X, Zhu J, Wang Y. et al. The higher serum endocan levels may be a risk factor for the onset of cardiovascular disease: A meta-analysis. Medicine (Baltimore) 2018;97:e13407. PubMed PMC

Aminuddin A, Cheong SS, Roos NAC, Ugusman A. Smoking and Unstable Plaque in Acute Coronary Syndrome: A Systematic Review of The Role of Matrix Metalloproteinases. Int J Med Sci. 2023;20:482–92. PubMed PMC

Osenkowski P, Toth M, Fridman R. Processing, shedding, and endocytosis of membrane type 1-matrix metalloproteinase (MT1-MMP) J Cell Physiol. 2004;200:2–10. PubMed

Ikemoto T, Hojo Y, Kondo H, Takahashi N, Hirose M, Nishimura Y. et al. Plasma endoglin as a marker to predict cardiovascular events in patients with chronic coronary artery diseases. Heart Vessels. 2012;27:344–51. PubMed

Kjeldsen EW, Thomassen JQ, Frikke-Schmidt R. HDL cholesterol concentrations and risk of atherosclerotic cardiovascular disease - Insights from randomized clinical trials and human genetics. Biochim Biophys Acta Mol Cell Biol Lipids. 2022;1867:159063. PubMed